Effect of Rosiglitazone and Insulin Combination Therapy on Inflammation Parameters and Adipocytokine Levels in Patients with Type 1 DM

Table 3

Comparisons between the groups for inflammatory marker, FFA, and serum adipocytokine levels at baseline and at the final visit (week 16).

Parameters	Randomization visit			Final visit
	Group 1; Insulin + Ros	Group 2; Insulin only		Group 1; Insulin + Ros	Group 2; Insulin only
ESR (mm/h)	11.85 ± 11.36	10.89 ± 10.39	0.969	14.44 ± 13.14	11.00 ± 8.76	0.599
Fibrinogen (g/L)	4.00 ± 1.08	3.46 ± 0.90	0.047	3.46 ± 0.90	3.11 ± 0.92	0.271
hs-CRP (mg/L)	2.32 ± 2.64	1.41 ± 1.69	0.361	1.76 ± 1.14	1.76 ± 2.31	0.443
FFA (mEq/L)	0.57 ± 0.43	0.49 ± 0.25	0.917	0.53 ± 0.28	0.47 ± 0.26	0.518
Resistin (ng/mL)	6.96 ± 3.06	7.16 ± 2.30	0.489	4.99 ± 2.64	5.57 ± 2.48	0.650
Leptin (ng/mL)	25.8 ± 17.6	16.72 ± 16.1	0.130	20.1 ± 12.55	14.0 ± 13.4	0.724
Adiponectin; (µg/mL)	17.48 ± 10.71	11.90 ± 5.23	0.760	19.81 ± 11.21	15.98 ± 9.47	0.091

Ros: rosiglitazone; ESR: erythrocyte sedimentation rate; hs-CRP: high-sensitivity C-reactive protein; FFA: free fatty acids.